We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+30.39%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$82.5M
AUM Growth
+$14.4M
Cap. Flow
-$5.05M
Cap. Flow %
-6.12%
Top 10 Hldgs %
85.52%
Holding
33
New
3
Increased
2
Reduced
3
Closed
7

Top Buys

Rank Stock Value
1
ARLZ
Aralez Pharmaceuticals Inc.
ARLZ
+$1.79M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$2.68M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$2.43M
3
AMRI
Albany Molecular Research Inc
AMRI
+$1.46M
4
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$269K

Sector Composition

Rank Sector Weight
1 Healthcare 64.22%
2 Miscellaneous 35.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANIP icon
1
ANI Pharmaceuticals
ANIP
$1.69B
$19.3M 23.35%
345,000
-50,000
-13% -$2.43M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$827B
$15.7M 19.05%
75,000
+50,000
+200% +$10.4M
ASRT
3
DELISTED
Assertio
ASRT
$6.87M 8.32%
5,833
– –
PFE icon
4
Pfizer
PFE
$160B
$6.16M 7.47%
184,450
– –
DGX icon
5
Quest Diagnostics
DGX
$27B
$5.39M 6.53%
66,208
– –
AORT icon
6
Artivion
AORT
$1.3B
$4.72M 5.73%
400,000
– –
AMRI
7
DELISTED
Albany Molecular Research Inc
AMRI
$4.06M 4.93%
302,400
-100,000
-25% -$1.46M
QLTI
8
DELISTED
QLT Inc
QLTI
$3.06M 3.71%
2,157,200
– –
ANIP icon
9
PUT
ANI Pharmaceuticals
ANIP
$1.69B
$2.79M 3.38%
+50,000
New +$2.43M
AMAG
10
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
$2.51M 3.05%
+105,000
New +$2.41M
ASRT
11
CALL
DELISTED
Assertio
ASRT
$1.96M 2.38%
1,667
– –
ARLZ
12
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$1.9M 2.3%
575,000
+475,000
+475% +$1.79M
TWM icon
13
CALL
ProShares UltraShort Russell2000
TWM
$44M
$1.74M 2.11%
2,500
– –
CYTK icon
14
Cytokinetics
CYTK
$10.8B
$949K 1.15%
100,000
– –
VIXY icon
15
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$212M
$916K 1.11%
+63
New +$1.04M
TWM icon
16
ProShares UltraShort Russell2000
TWM
$44M
$871K 1.06%
1,250
– –
SGNT
17
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$749K 0.91%
50,000
– –
AMRI
18
CALL
DELISTED
Albany Molecular Research Inc
AMRI
$672K 0.81%
50,000
– –
AORT icon
19
CALL
Artivion
AORT
$1.3B
$591K 0.72%
50,000
– –
SGNT
20
CALL
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$524K 0.64%
35,000
– –
ZGNX
21
DELISTED
Zogenix, Inc.
ZGNX
$256K 0.31%
31,850
– –
ARLZ
22
CALL
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$248K 0.3%
75,000
-100,000
-57% -$377K
SEEL
23
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
FCSC
24
DELISTED
Fibrocell Science Inc.
FCSC
$170K 0.21%
9,851
– –
QLTI
25
CALL
DELISTED
QLT Inc
QLTI
$142K 0.17%
100,000
– –
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Healthcare Value Capital held 33 positions worth $82.5M, up 21% from $68.1M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Healthcare Value Capital withdrew a net $5.05M in Q2 2016, closing 7 positions and reducing 3 holdings. Its most notable exit was Allergan plc, an estimated $2.68M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 70% a quarter earlier, followed by Miscellaneous.

Against the trend, Healthcare Value Capital added an estimated $1.79M to Aralez Pharmaceuticals Inc..

  • Healthcare Value Capital added most to Aralez Pharmaceuticals Inc. in Q2 2016, an estimated $1.79M increase.
  • Healthcare Value Capital's biggest Q2 2016 reduction was ANI Pharmaceuticals, cutting an estimated $2.43M.
  • Healthcare Value Capital fully exited Allergan plc in Q2 2016, selling an estimated $2.68M.
  • Healthcare Value Capital's ten largest holdings make up 86% of its $82.5M portfolio in Q2 2016.
  • Healthcare Value Capital opened 3 new positions and closed 7 in Q2 2016.
  • Healthcare Value Capital's portfolio value rose 21% quarter-over-quarter to $82.5M.

Based on Healthcare Value Capital's 13F filing for Q2 2016, filed 15 Aug 2016.